免責聲明 EF002 執行董事胡定旭先生、傅廷美先生、周鵬先生及羅詠詩女士。 EF002 | 香港 | | | --- | --- | | 代扣所得稅信息 | | | 股息所涉及的代扣所得稅 | 不適用 | | 發行人所發行上市權證/可轉換債券的相關信息 | | | 發行人所發行上市權證/可轉換債券 | 不適用 | | 其他信息 | | | 可就部分股息行使貨幣選擇權只適用於香港中央結算(代理人)有限公司。 | | | 發行人董事 | | | 於本公告日期及自單寶杰先生之辭任於同日生效後，董事會成員包括執行董事于海先生及楊敏女士；非執行董事葛路女士；獨立非 | | 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | --- | --- | | | 股票發行人現金股息（可選擇貨幣）公告 | | 發行人名稱 | 華潤醫療控股有限公司 | | 股份代號 | 01515 | | 多櫃檯股份代號及貨幣 | 不適用 ...

Financial Performance Overview [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=1&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income) China Resources Medical Holdings Company Limited's revenue decreased by 9.1% to RMB 4.525 billion in H1 2025, with gross profit down 31.2% to RMB 713 million. Profit for the period was RMB 374 million, a 26.9% decrease, and profit attributable to owners of the parent was RMB 340 million, with basic earnings per share of RMB 0.27 2025 H1 Key Financial Data (Profit or Loss Statement) | Metric | 2025 (RMB '000) | 2024 (RMB '000) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Revenue | 4,524,803 | 4,976,334 | -9.1% | | Cost of Sales | (3,812,276) | (3,939,986) | -3.2% | | Gross Profit | 712,527 | 1,036,348 | -31.2% | | Profit Before Tax | 508,123 | 627,328 | -19.0% | | Income Tax | (133,875) | (115,673) | +15.7% | | Profit for the Period | 374,248 | 511,655 | -26.9% | | Attributable to Owners of the Parent | 339,521 | 433,949 | -21.7% | | Basic Earnings Per Share (RMB) | 0.27 | 0.34 | -20.6% | [Condensed Consolidated Statement of Financial Position](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2025, total assets were RMB 13.586 billion, a 2.0% increase from year-end 2024. Net current liabilities improved to RMB -1.210 billion from RMB -1.260 billion, and total equity rose 3.6% to RMB 7.769 billion June 30, 2025 Key Financial Data (Balance Sheet) | Metric | June 30, 2025 (RMB '000) | December 31, 2024 (RMB '000) | Change | | :--- | :--- | :--- | :--- | | Total Non-current Assets | 10,071,137 | 10,079,012 | -0.1% | | Total Current Assets | 3,514,492 | 3,239,138 | +8.5% | | **Total Assets** | **13,585,629** | **13,318,150** | **+2.0%** | | Total Current Liabilities | 4,724,639 | 4,499,386 | +5.0% | | Total Non-current Liabilities | 1,092,346 | 1,320,696 | -17.3% | | **Total Liabilities** | **5,816,985** | **5,820,082** | **-0.1%** | | Net Current Liabilities | (1,210,147) | (1,260,248) | Improved | | Equity Attributable to Owners of the Parent | 6,449,385 | 6,213,536 | +3.8% | | Non-controlling Interests | 1,319,259 | 1,284,532 | +2.7% | | **Total Equity** | **7,768,644** | **7,498,068** | **+3.6%** | Notes to the Financial Statements [Company Information](index=5&type=section&id=Company%20Information) China Resources Medical Holdings Company Limited is incorporated in the Cayman Islands, primarily engaged in integrated medical services, hospital management, and sales of pharmaceuticals and medical devices in mainland China - **Company registered in the Cayman Islands**[7](index=7&type=chunk) - **Primary businesses** include integrated medical services; providing hospital management services, selling pharmaceuticals, medical devices and consumables, and offering other services[7](index=7&type=chunk) [Basis of Preparation and Changes in Accounting Policies](index=5&type=section&id=Basis%20of%20Preparation%20and%20Changes%20in%20Accounting%20Policies) The interim financial report is prepared in accordance with IAS 34, using the historical cost convention and consistent accounting policies with the 2024 annual financial statements. Despite current liabilities exceeding current assets as of June 30, 2025, management deems the going concern basis appropriate due to sufficient bank facilities. Accounting policy changes had no significant impact this period - **Prepared in accordance with IAS 34 Interim Financial Reporting**[8](index=8&type=chunk) - **Accounting policies are consistent** with the **2024** annual financial statements, except for changes expected to be reflected in the **2025** annual financial statements[8](index=8&type=chunk) - As of **June 30, 2025**, current liabilities exceeded current assets by **RMB 1.21 billion**, but with approximately **RMB 8.02 billion** in unutilised bank facilities, management considers the going concern basis appropriate[9](index=9&type=chunk) - **Application of amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates — Lack of Exchangeability** had no significant impact on this interim financial report[10](index=10&type=chunk) [Operating Segment Information](index=6&type=section&id=Operating%20Segment%20Information) The Group operates in two reportable segments: hospital business, covering outpatient and inpatient services of self-owned hospitals, and other businesses, including operational management and supply chain services for associate and IOT/OT hospitals. Segment performance is assessed based on adjusted profit before tax, with inter-segment transactions at market prices - **Reportable segments**: Hospital Business (outpatient and inpatient services of self-owned hospitals) and Other Businesses (operational management, supply chain, and other services to associate and IOT/OT hospitals)[16](index=16&type=chunk) - **Segment performance is assessed** based on adjusted profit/loss before tax, excluding fair value changes, unallocated income/gains, exchange differences, and unallocated losses/expenses[12](index=12&type=chunk) - **Inter-segment transactions are conducted** at prices used for sales to third parties at the time of transaction[14](index=14&type=chunk) [Segment Revenue and Results](index=7&type=section&id=Segment%20Revenue%20and%20Results) In H1 2025, hospital business revenue decreased 7.4% to RMB 4.259 billion, with segment results down 51.1% to RMB 255 million. Other business revenue fell 29.3% to RMB 266 million, but segment results surged 96.9% to RMB 292 million due to a one-off compensation payment Segment Revenue and Results (RMB '000) | Metric | Hospital Business (2025) | Hospital Business (2024) | Other Businesses (2025) | Other Businesses (2024) | | :--- | :--- | :--- | :--- | :--- | | Segment Revenue | 4,258,616 | 4,600,005 | 266,187 | 376,329 | | Segment Costs | (3,588,771) | (3,677,361) | (223,505) | (262,625) | | Segment Results | 254,708 | 520,836 | 292,340 | 148,486 | - **Hospital business revenue decreased by 7.4%** year-on-year, and segment results decreased by **51.1%** year-on-year[17](index=17&type=chunk)[19](index=19&type=chunk) - **Other business revenue decreased by 29.3%** year-on-year, while segment results significantly increased by **96.9%** year-on-year[17](index=17&type=chunk)[19](index=19&type=chunk) [Segment Assets and Liabilities](index=9&type=section&id=Segment%20Assets%20and%20Liabilities) As of June 30, 2025, hospital business segment assets were RMB 8.781 billion, and other business segment assets were RMB 1.366 billion. Segment liabilities exclude interest-bearing bank borrowings and other unallocated head office and corporate liabilities Segment Assets and Liabilities (RMB '000) | Metric | Hospital Business (Jun 30, 2025) | Hospital Business (Dec 31, 2024) | Other Businesses (Jun 30, 2025) | Other Businesses (Dec 31, 2024) | | :--- | :--- | :--- | :--- | :--- | | Segment Assets | 8,780,580 | 8,889,773 | 1,366,473 | 1,348,719 | | Segment Liabilities | 4,799,278 | 4,865,659 | 21,617 | 20,870 | - **Segment assets exclude** goodwill, unallocated investments in associates, financial assets at fair value through profit or loss, cash and cash equivalents, pledged deposits, and other unallocated head office and corporate assets[13](index=13&type=chunk) - **Segment liabilities exclude** interest-bearing bank borrowings and other unallocated head office and corporate liabilities[13](index=13&type=chunk) [Revenue Breakdown](index=10&type=section&id=Revenue%20Breakdown) In H1 2025, integrated medical services revenue was RMB 4.2

Group 1 - The core point of the article is the resignation of Mr. Dan Baojie from the position of Executive Director of China Resources Medical Holdings Company Limited, effective from August 26, 2025 [1] Group 2 - The announcement indicates a change in leadership within the company, which may impact its strategic direction and operations [1] - The reason for Mr. Dan Baojie's resignation is attributed to other work arrangements, suggesting potential shifts in his professional commitments [1]

华润医疗(01515)发布公告，单宝杰先生因其他工作安排辞任执行董事职务，自2025年8月26日起生效。 于单先生辞任执行董事后并于同日起，彼亦不再担任公司副总裁。 ...

智通财经APP讯，华润医疗(01515)发布公告，单宝杰先生因其他工作安排辞任执行董事职务，自2025年 8月26日起生效。于单先生辞任执行董事后并于同日起，彼亦不再担任公司副总裁。 ...

（於開曼群島註冊成立的有限責任公司） （股份代號：1515） 董事名單及其角色和職能 華潤醫療控股有限公司的董事會（「董事會」）成員載列如下： 執行董事 于海， 董事長兼總裁 楊敏， 首席財務官 非執行董事 葛路 獨立非執行董事 胡定旭 傅廷美 周鵬 羅詠詩 董事會設立三個委員會，即審核委員會、提名委員會及薪酬委員會。各董事會成 員在該等委員會所擔任的職位載列如下。 | | 委員會 | 審核 | 提名 | 薪酬 | | --- | --- | --- | --- | --- | | 董事 | | 委員會 | 委員會 | 委員會 | | 于海 | | | C | | | 楊敏 | | | | | | 葛路 | | | | M | | 胡定旭 | | | M | C | | 傅廷美 | | C | | M | | 周鵬 | | M | | | | 羅詠詩 | | M | M | | 附註： C 有關董事委員會之主席 M 有關董事委員會之成員 中國，2025年8月26日 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 執行董事辭任 華 潤 醫 療 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）之 董 事（「 董 事」）會（「董事會」）謹此宣佈，單寶杰先生（「單先生」）因其他工作安排辭任執行董 事 職務 ，自 2025 年 8 月26 日起 生效 。 於單 先生 辭任 執 行董 事後 並 於同 日起 ， 彼亦 不再擔任本公司副總裁。單先生已確認，彼與董事會概無意見分歧，亦無任何有 關彼辭任的事宜須提呈本公司股東及香港聯合交易所有限公司垂注。 董事會藉此衷心感謝單先生任內作為執行董事對本集團作出的寶貴貢獻。 承董事會命 華潤醫療控股有限公司 董事長 于海 中國，2025年8月26日 於 本 公 告 日 期 及 作 出 上 述 變 更 後 ， ...

Core Insights - China Resources Medical is actively responding to new compliance requirements in the healthcare service industry by optimizing its business structure and steadily exiting the IOT business [1][2] - The company operates 105 medical institutions across 10 provinces and cities in China, with a reported total revenue of 9.855 billion yuan and a net profit of 672 million yuan for the year 2024 [1] - The distinction between "consolidated profit" and "distributable profit" is emphasized in the financial disclosures, particularly regarding the income from non-profit hospitals [1] Group 1 - The company has terminated IOT agreements with several hospitals, including Beijing Coal Group General Hospital and Shunyi District Airport Hospital, ensuring a smooth transition [1] - The financial report highlights the importance of accurately disclosing profit components, particularly the need to differentiate between the surplus from non-profit hospitals and distributable profits [1] - Future paths for state-owned enterprises in healthcare may include transitioning non-profit institutions to for-profit status and clarifying profit distribution in financial disclosures [1] Group 2 - As a benchmark for state-owned enterprises in healthcare, China Resources Medical balances its public health mission with shareholder return responsibilities, which raises development expectations [2] - The company integrates ESG principles into its development strategy, focusing on grassroots healthcare construction and public health responsibilities [2] - The exit from the IOT business is a significant step in compliance construction, with plans to optimize revenue structure and control operational costs to enhance efficiency [2]

Core Viewpoint - China Resources Medical's net profit is expected to be halved after excluding one-time gains, facing dual pressures from medical insurance cost control and strategic transformation, exemplified by the shutdown of Huaiyin Hospital, acquired for 883 million yuan, after three years of operation [1][2][3]. Group 1: Financial Performance - The announcement reveals two main reasons for the decline in performance: ongoing pressure from medical insurance cost control, which has compressed average costs per patient and significantly narrowed operating profit margins [2][4]. - The strategic transformation pain is evident as the company gradually divests from the previously profitable IOT (Investment-Operation-Transfer) business model, leading to a sharp reduction in related revenues [2][4]. - Without the one-time gain of approximately 210 million yuan from the Yanhua IOT agreement expected in the first half of 2025, the core profitability decline would be even more alarming, projected to drop by 55% to 60%, nearly halving [2][4]. Group 2: Strategic Adjustments - A significant strategic contraction has drawn market attention, as the company plans to shut down Jiangsu Huaiyin Hospital, acquired for 883 million yuan in 2021, due to ongoing operational deterioration and increasing losses [3][4]. - Financial data indicates that this acquisition has become a "hot potato," with revenues dropping over 50% in 2022 and over 60% in 2023, leading to cumulative losses nearing 200 million yuan over three years [4]. - In response to these challenges, the company stated it will focus on improving revenue structure, promoting refined management, strictly controlling operating costs, and enhancing operational efficiency in the second half of the year [4]. Group 3: Industry Context - The performance warning and project shutdown reflect the broader challenges faced by medical groups under the backdrop of public hospital reform and deepening medical insurance cost control, highlighting the need for a reconstruction of profit models [4]. - The company, as the only listed platform in China Resources Group's health sector, operates 105 medical institutions with over 20,000 beds across 10 provinces, yet its revenue for 2024 has already declined by 2.5% year-on-year, with the impact of medical insurance cost control explicitly mentioned in the annual report [4].

格隆汇8月14日丨华润医疗(01515.HK)公布，谨定于2025年8月26日(星期二)举行董事会会议，以考虑及 通过公司及其附属公司截至2025年6月30日止六个月的综合中期业绩及其发布、考虑派发中期股息(如 有)，以及处理其他事项。 ...